CTI Makes Over Zevalin As Front-Line NHL Therapy Booster
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug is on FDA fast track and new partner is on board, but firm must still clear roadblocks to win acceptance in the marketplace.
You may also be interested in...
CTI Bags Cash, Turns Its Back On Zevalin
Buyer Spectrum downplays supplemental BLA delay in front-line non-Hodgkins lymphoma.
CTI Bags Cash, Turns Its Back On Zevalin
Buyer Spectrum downplays supplemental BLA delay in front-line non-Hodgkins lymphoma.
Broader Zevalin NHL Label: 18 Times More Use?
New indication sought in sBLA could mean whopper sales, CTI exec says.